Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Platelet Lysate for Post-COVID-19 Syndrome
NCT04487691Terminated
- Sponsor
- Regenexx
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Blood Coagulation Factors
- Countries
- 1
01
Overview
Randomised, double-blind trial of platelet lysate in post-COVID-19 condition (PCC) (2 arms), sponsored by Regenexx. Primary endpoints: Forced Vital Capacity at 8 weeks and FEV1/FVC Ratio at 8 weeks. Started Dec 2020; status: terminated.
02
Drugs
platelet lysate
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT04487691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04487691.